Meta AnalysisID 2820

吲哚美辛控制重度颅脑损伤后继发性颅内高压 [Cochrane方案]

CRD42015027139

To determine the efficacy, and gather evidence on safety, of indomethacin for people with severe traumatic brain injury.

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final meta_analysis record.

Meta Analysis Id
2820
Evidence Id
11378
Core Evidence Id
11378
Source Meta Analysis Id
2764
Herb2 Meta Analysis Id
HBMA002764
Crd Id
CRD42015027139
Title
Indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury [Cochrane Protocol]
Review Question
To determine the efficacy, and gather evidence on safety, of indomethacin for people with severe traumatic brain injury.
Study Type Included
Randomised controlled trials are eligible for inclusion in this review.
Condition Being Studied
The Cochrane Injuries Group
Participant
We will include adults ≥ 18 years old, presenting with severe brain trauma (defined as having an initial Glasgow Coma Scale (GCS) score of < 8), due to any cause, and associated with elevated intracranial pressure (> 20 mmHg) with no previous decompressive surgery despite other co-morbilities.
Animal
Human Disease Modelled
Intervention
We will assess indomethacin compared with any control group, making sure that the comparison allows the determination of the specific effects of indomethacin (that is, the use of indomethacin must be the only difference between the intervention and control study arms). The intervention can be given to participants for any length of time.
Comparator Control
We will assess indomethacin compared with any control group, making sure that the comparison allows the determination of the specific effects of indomethacin (that is, the use of indomethacin must be the only difference between the intervention and control study arms). The intervention can be given to participants for any length of time.
Main Outcome
<ol> Intracranial pressure (mmHg) (measured by an epidural, subdural or intraparenchymatous brain catheter with continuous monitoring). We will group intracranial pressure values measured at similar time points across studies. </ol>
Outcome Measure
Additional Outcome
<ol> Mortality, measured at approximately one month after the start of therapy. Adverse effects considered as serious by either the patient or the clinician. Disability, measured by the Glasgow Outcome Scale (GOS) or any other measures of neurological functioning or disability, six months after the start of therapy. Differences in quality of life (measured with a validated scale, such as the 36-Item Short Form Health Survey (SF-36) or the Davidson Trauma Scale (DTS), six months after the start of therapy. </ol>
Study Method
Keyword
Brain Injuries; Humans; Indomethacin; Intracranial Hypertension; Treatment Effectiveness
Contact
Fernando G Baccaro [email protected]
Organisational Affiliation
The Cochrane Collaboration http://www.cochrane.org/
Funding Source
None, Instituto de Efectividad Clínica y Sanitaria
Other Selection Criteria
Final Publication
Same Topic Review
Published Protocol
Review Type
Language
English
Country
Argentina
Review Stage
Review Ongoing
First Submission Date
Registration Date
2015-10-14
Anticipated Start Date
2015-05-15
Anticipated Completion Date
2017-05-15
Title Cn
吲哚美辛控制重度颅脑损伤后继发性颅内高压 [Cochrane方案]
Title En
Indomethacin in controlling intracranial hypertension secondary to severe traumatic brain injury [Cochrane Protocol]
Bilingual Status
complete